<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455533</url>
  </required_header>
  <id_info>
    <org_study_id>CA163-100</org_study_id>
    <secondary_id>EUDRACT 2006-003047-24</secondary_id>
    <nct_id>NCT00455533</nct_id>
  </id_info>
  <brief_title>Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer</brief_title>
  <official_title>A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effectiveness of ixabepilone when given after doxorubicin plus
      cyclophosphamide (AC) compared to standard treatment of paclitaxel given after doxorubicin
      plus cyclophosphamide in patients with early stage breast cancer. In addition the study will
      verify predefined biomarkers as well as discover new biomarkers that could identify patients
      who are more likely to respond to ixabepilone than standard paclitaxel based therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Pathologic Complete Response (pCR)</measure>
    <time_frame>at surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy)</time_frame>
    <description>The pCR was defined as no histologic evidence of residual invasive adenocarcinoma in the breast and axillary lymph nodes, with or without the presence of ductal carcinoma in situ (DCIS) in the breast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Pathologic Complete Response (pCR) in Biomarker-Defined Populations</measure>
    <time_frame>pCR evaluated at time of surgery (4-6 weeks after the last dose of therapy); mandatory tumor tissue biopsy obtained prior to treatment.</time_frame>
    <description>Beta III tubulin positivity determined by cross-validation method. Optimal cutoff: ≥46% tumor cells staining at 2 plus or 3 plus intensity (corresponding Beta III tubulin positivity=39.4%). Pre-specified cutoff of Beta III tubulin positivity: ≥50% 2plus or 3plus cells (corresponding prevalence=38.5%). Optimal cutoffs for TACC3 and CAPG positivity determined by cross-validation method: 6.889 and 6.844 [log2 normalized intensity units], respectively (corresponding to prevalence rates of 43.3% and 44.3%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Pathologic Complete Response (pCR) in 20- and 26-Gene Model Subgroups</measure>
    <time_frame>pCR evaluated at time of surgery (4-6 weeks after the last dose of therapy); mandatory tumor tissue biopsy obtained prior to treatment.</time_frame>
    <description>For each of the 2 biomarker sets (20-gene or 26-gene), a multi-gene model was built using penalized logistic regression on all pharmacogenomic evaluable subjects for each treatment arm separately. Receiver Operating Characteristic (ROC) plots for separate arm using 5 fold cross validation were generated. ROC for separate arms using cross over were also added. Further analysis on the multiple gene models (as mentioned in the SAP) was planned only based on the initial findings from the 2 ROC plots. For 20- and 26-gene models, ROC curves generated for each study arm did not indicate that these multi-gene models differentially predicted for pCR between the treatment arms, so further analyses to estimate the optimal cut-off and the pCR rates were not conducted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Objective Response</measure>
    <time_frame>after the last dose of either ixabepilone or paclitaxel (at 12 weeks) but before surgery (4-6 weeks after the last dose of 12 weeks of therapy)</time_frame>
    <description>Clinical response was defined as the number of participants who achieved modified World Health Organization's tumor response criteria of clinical complete response (complete disappearance of all clinically palpable detectable malignant disease and/or disappearance of radiological evidence of tumor in the breast and ipsilateral axillary lymph nodes) or clinical partial response (clinical evidence of a reduction in total tumor size of &gt;= 50% in the overall sum of the products of diameters of breast and axillary lesions), divided by the number of randomized participants in that arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Breast Conservation Surgery</measure>
    <time_frame>at surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy)</time_frame>
    <description>Number of randomized participants requiring breast conservation surgery following study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Combined pCR and Minimal Residual Cancer Burden (RCB) 1</measure>
    <time_frame>at surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy)</time_frame>
    <description>Combined pCR and RCB-1 was defined as participants with no histologic evidence of residual invasive adenocarcinoma in the breast and axillary lymph nodes, with or without the presence of DCIS in the breast plus subjects with RCB-1 following the RCB calculation based on data entered by the investigator sites in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomized Participants With Non-missing pCR &amp; Biomarker Expression (GENE [Probe Set]), to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR</measure>
    <time_frame>pCR evaluated at time of surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy obtained prior to treatment.</time_frame>
    <description>Relevance of biomarker in differentiation between ixabepilone &amp; paclitaxel evaluated by logistic regression with pCR as response. Statistical analyses include: 1) the likelihood ratio test between the full model (PCR~Biomarker:Treatment:estrogen receptor [ER]) &amp; reduced model (PCR~Treatment:ER); 2) the likelihood ratio test between the full model (PCR~Biomarker:Treatment) &amp; reduced model (PCR~Biomarker+Treatment); 3) the contrast of the interaction between treatment &amp; biomarker expression within ER Negative subjects from the full model(PCR~Biomarker:Treatment:ER). A:B represents A,B &amp; A*B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomized Participants With Non-missing pCR &amp; Biomarker Expression (GENE [Probe Set]) to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR/RCB1</measure>
    <time_frame>pCR evaluated at time of surgery (4-6 weeks after the last dose of therapy); mandatory tumor tissue biopsy obtained prior to treatment.</time_frame>
    <description>Relevance of biomarker in differentiation between ixabepilone &amp; paclitaxel evaluated by logistic regression with pCR/RCB1 as response. Statistical analyses include: 1) likelihood ratio test between the full model (pCR/RCB1~Biomarker:Treatment: ER) &amp; reduced model (pCR/RCB1~Treatment:ER); 2) likelihood ratio test between the full model (pCR/RCB1 Biomarker:Treatment) &amp; reduced model (pCR/RCB1~Biomarker+Treatment); 3) contrast of the interaction between treatment &amp; biomarker expression within ER Negative subjects from the full model (pCR/RCB1~Biomarker:Treatment:ER). A:B represents A,B &amp; A*B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With pCR and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-Specified Thresholds</measure>
    <time_frame>: pCR evaluated at time of surgery (4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy obtained prior to treatment.</time_frame>
    <description>Percentage of participants with pCR in MDR1 IHC positive and negative groups using 2 pre-specified thresholds,. The first pre-specified threshold for MDR1-positivity (Mem) =Any membrane staining. The second pre-specified threshold for MDR1-positivity (Mem+Cyto)=Any membrane staining or at least 200 Cytoplasmic H-score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With pCR/RCB1 and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-specified Thresholds</measure>
    <time_frame>pCR evaluated at time of surgery (4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy obtained prior to treatment.</time_frame>
    <description>Percentage of participants with pCR/RCB1 in MDR1 IHC positive and negative groups using 2 pre-specified thresholds,. The first pre-specified threshold for MDR1-positivity (Mem) =Any membrane staining. The second pre-specified threshold for MDR1-positivity (Mem+Cyto)=Any membrane staining or at least 200 Cytoplasmic H-score .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With pCR and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-specified Thresholds, Estrogen-Receptor (ER) Negative Participants</measure>
    <time_frame>pCR evaluated at time of surgery (4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy obtained prior to treatment.</time_frame>
    <description>Percentage of ER negative participants with pCR and MDR1 immunohistochemistry (IHC) positivity using 2 pre-specified thresholds, stratified by biomarker status. The first pre-specified threshold for MDR1-positivity (Mem)=Any membrane staining. The second pre-specified threshold for MDR1-positivity (Mem+Cyto)=Any membrane staining or at least 200 Cytoplasmic H-score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Biomarker Based on Optimal Threshold (Biomarker Positive Participants)</measure>
    <time_frame>pCR evaluated at time of surgery (4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy and mRNA samples obtained prior to treatment</time_frame>
    <description>Percentage of participants having the following optimal biomarker thresholds as computed from the cross-validation method (cutoff of biomarker positive [with 90% confidence interval by Bootstrap method]): Beta 3 Tubulin IHC (45.866 [5, 83.9]); TACC3 mRNA (6.714 [6.312, 7.192]); CAPG mRNA (6.739 [5.728, 7.298]). Optimal thresholds for a 20-gene model and a 26-gene model were also planned; however, these were not determined because preliminary analyses did not indicate that they would not differentiate pCR rates between treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Safety Summary: Deaths, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Drug-Related AEs, and Most Common Treatment-Related Non-Hematologic Adverse Events (TNAEs) Occuring in &gt;=10% of Participants</measure>
    <time_frame>prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of 12 weeks of study therapy</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. By Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grades</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Any Drug-Related AEs and Gastrointestinal AEs by System Organ Class</measure>
    <time_frame>prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of 12 weeks of study therapy</time_frame>
    <description>MCT=musculoskeletal and connective tissue, GDASC=general disorders and administration site conditions, RTM=respiratory, thoracic and mediastinal disorders, NBMUCP=neoplasms benign, malignant and unspecified (including cysts and polyps). Drug related adverse events are those events with relationship to study therapy of certain, probable, possible or missing. Subjects may have more than one event within a class. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>On-Study Hematology: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase</measure>
    <time_frame>prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of 12 weeks of study therapy during ixabepilone or paclitaxel treatment phase</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>On-Study Liver Function: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase</measure>
    <time_frame>prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of study therapy during ixabepilone or paclitaxel treatment phase</time_frame>
    <description>Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST). AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>On-Study Renal Function: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase</measure>
    <time_frame>prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of 12 weeks of study therapy during ixabepilone or paclitaxel treatment phase</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants by Dose for AC</measure>
    <time_frame>12 weeks (4 3-week cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants by Dose for Ixabepilone/Paclitaxel</measure>
    <time_frame>12 weeks (4 3-week cycles for ixabepilone and 12 weekly doses for paclitaxel)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for First Dose Reduction of AC</measure>
    <time_frame>12 weeks (4 3-week cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for First Dose Reduction of Ixabepilone/Paclitaxel</measure>
    <time_frame>12 weeks (4 3-week cycles for ixabepilone and 12 weekly doses for paclitaxel)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Course Delay and Reason for Delay for AC</measure>
    <time_frame>12 weeks (4 3-week cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Dose Delay and Reason for Dose Delay for Ixabepilone/Paclitaxel</measure>
    <time_frame>12 weeks (4 3-week cycles for ixabepilone and 12 weekly doses for paclitaxel)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">384</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixabepilone</intervention_name>
    <description>Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Epothilone</other_name>
    <other_name>IXEMPRA®</other_name>
    <other_name>BMS-247550</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Histologically confirmed primary invasive adenocarcinoma of the breast , T2-3, N0-3,
             M0, with tumor size of ≥ 2 cm

          -  All patients with early stage breast adenocarcinoma may enroll irrespective of
             receptor status

          -  No prior treatment for breast cancer excluding therapy for DCIS

          -  Karnofsky performance status of 80 - 100

          -  left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram or multiple gated
             acquisition (MUGA)

          -  Adequate hematologic, hepatic and renal function

        Exclusion Criteria

          -  women of child-bearing potential (WOCBP) unwilling or unable to use an acceptable
             method to avoid pregnancy during and up to 8 weeks after the last dose of the
             investigational drug

          -  Women who are pregnant or breastfeeding

          -  Inflammatory or metastatic breast cancer

          -  Unfit for breast and/or axillary surgery

          -  Evidence of baseline sensory or motor neuropathy

          -  Significant history of cardiovascular disease, serious intercurrent illness or
             infections including known human immu immunodeficiency virus (HIV) infection

          -  History of prior anthracycline therapy Allergies to any study medication or Cremophor®
             EL
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Oncology &amp; Hematology Associates</name>
      <address>
        <city>Coral Spring</city>
        <state>Florida</state>
        <zip>33065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Research Institute</name>
      <address>
        <city>Davie</city>
        <state>Florida</state>
        <zip>33328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Specialists Of Palm Beaches</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center, Inc</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1417</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1180AAX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1650</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40235</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110 095</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bhopal</city>
        <zip>462001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hyderabad</city>
        <zip>500 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mumbai</city>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vellore</city>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Callao</city>
        <zip>2</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lima</city>
        <zip>34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Davao City</city>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Quezon City</city>
        <zip>1114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Coventry</city>
        <state>Warwickshire</state>
        <zip>CV22DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2007</study_first_submitted>
  <study_first_submitted_qc>April 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2007</study_first_posted>
  <results_first_submitted>March 4, 2011</results_first_submitted>
  <results_first_submitted_qc>March 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2011</results_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Epothilones</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 384 participants were enrolled in this study; 71 did not receive any study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Doxorubicin / Cyclophosphamide (AC)</title>
          <description>60 mg/m^2 doxorubicin and 600 mg/m^2 cyclophosphamide (AC) every 3 weeks for 4 cycles (12 weeks).</description>
        </group>
        <group group_id="P2">
          <title>Ixabepilone</title>
          <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
        </group>
        <group group_id="P3">
          <title>Paclitaxel</title>
          <description>Paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period One: Initial Chemotherapy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="313"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event Not Related to Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Reported</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other--Need Reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Drug Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Request to Discontinue Study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject No Longer Meets Study Criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period Two: Randomized Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="145">148 randomized, 145 randomized and treated with ixabepilone</participants>
                <participants group_id="P3" count="144">147 randomized, 144 randomized and treated with paclitaxel</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other - need reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Drug Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ixabepilone (Randomized Population)</title>
          <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
        </group>
        <group group_id="B2">
          <title>Paclitaxel (Randomized Population)</title>
          <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
            <count group_id="B2" value="147"/>
            <count group_id="B3" value="295"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.0" lower_limit="25.0" upper_limit="79.0"/>
                    <measurement group_id="B2" value="46.0" lower_limit="26.0" upper_limit="74.0"/>
                    <measurement group_id="B3" value="48.0" lower_limit="25.0" upper_limit="79.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status-Baseline</title>
          <description>Classifies patients according to their functional impairment. Scores range from 0-100, the lower the score, the worse the survival for most serious illnesses.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>100 - Normal no complaints; no evidence of disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 - Normal activity; minor signs of disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80 - Activity with effort; some signs of disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 - Unable to carry on normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=60 Needs increasing assistance up to Death (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal Status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Pre-Menopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peri-Menopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Menopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Pathologic Complete Response (pCR)</title>
        <description>The pCR was defined as no histologic evidence of residual invasive adenocarcinoma in the breast and axillary lymph nodes, with or without the presence of ductal carcinoma in situ (DCIS) in the breast.</description>
        <time_frame>at surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy)</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Pathologic Complete Response (pCR)</title>
          <description>The pCR was defined as no histologic evidence of residual invasive adenocarcinoma in the breast and axillary lymph nodes, with or without the presence of ductal carcinoma in situ (DCIS) in the breast.</description>
          <population>All randomized participants</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" lower_limit="18.6" upper_limit="30.8"/>
                    <measurement group_id="O2" value="25.2" lower_limit="19.4" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8921</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8966</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in pCR</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>6.7</ci_upper_limit>
            <estimate_desc>The difference in pCR rates and the confidence interval computed using the method of DerSimonian and Laird stratified by tumor size at baseline, estrogen receptor status, and clinical response to AC.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Clinical Objective Response</title>
        <description>Clinical response was defined as the number of participants who achieved modified World Health Organization’s tumor response criteria of clinical complete response (complete disappearance of all clinically palpable detectable malignant disease and/or disappearance of radiological evidence of tumor in the breast and ipsilateral axillary lymph nodes) or clinical partial response (clinical evidence of a reduction in total tumor size of &gt;= 50% in the overall sum of the products of diameters of breast and axillary lesions), divided by the number of randomized participants in that arm.</description>
        <time_frame>after the last dose of either ixabepilone or paclitaxel (at 12 weeks) but before surgery (4-6 weeks after the last dose of 12 weeks of therapy)</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Clinical Objective Response</title>
          <description>Clinical response was defined as the number of participants who achieved modified World Health Organization’s tumor response criteria of clinical complete response (complete disappearance of all clinically palpable detectable malignant disease and/or disappearance of radiological evidence of tumor in the breast and ipsilateral axillary lymph nodes) or clinical partial response (clinical evidence of a reduction in total tumor size of &gt;= 50% in the overall sum of the products of diameters of breast and axillary lesions), divided by the number of randomized participants in that arm.</description>
          <population>All randomized participants</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1" lower_limit="75.0" upper_limit="86.2"/>
                    <measurement group_id="O2" value="77.6" lower_limit="71.2" upper_limit="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Breast Conservation Surgery</title>
        <description>Number of randomized participants requiring breast conservation surgery following study treatment.</description>
        <time_frame>at surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy)</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Breast Conservation Surgery</title>
          <description>Number of randomized participants requiring breast conservation surgery following study treatment.</description>
          <population>All randomized participants</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9" lower_limit="35.1" upper_limit="49.0"/>
                    <measurement group_id="O2" value="32.7" lower_limit="26.3" upper_limit="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Combined pCR and Minimal Residual Cancer Burden (RCB) 1</title>
        <description>Combined pCR and RCB-1 was defined as participants with no histologic evidence of residual invasive adenocarcinoma in the breast and axillary lymph nodes, with or without the presence of DCIS in the breast plus subjects with RCB-1 following the RCB calculation based on data entered by the investigator sites in each arm.</description>
        <time_frame>at surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy)</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Combined pCR and Minimal Residual Cancer Burden (RCB) 1</title>
          <description>Combined pCR and RCB-1 was defined as participants with no histologic evidence of residual invasive adenocarcinoma in the breast and axillary lymph nodes, with or without the presence of DCIS in the breast plus subjects with RCB-1 following the RCB calculation based on data entered by the investigator sites in each arm.</description>
          <population>All randomized participants</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" lower_limit="24.2" upper_limit="37.2"/>
                    <measurement group_id="O2" value="33.3" lower_limit="26.9" upper_limit="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6186</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5806</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
            <estimate_desc>The difference in pCR/RCB-I rates and the confidence interval computed using the method of DerSimonian and Laird stratified by tumor size at baseline, estrogen receptor status, and clinical response to AC.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Randomized Participants With Non-missing pCR &amp; Biomarker Expression (GENE [Probe Set]), to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR</title>
        <description>Relevance of biomarker in differentiation between ixabepilone &amp; paclitaxel evaluated by logistic regression with pCR as response. Statistical analyses include: 1) the likelihood ratio test between the full model (PCR~Biomarker:Treatment:estrogen receptor [ER]) &amp; reduced model (PCR~Treatment:ER); 2) the likelihood ratio test between the full model (PCR~Biomarker:Treatment) &amp; reduced model (PCR~Biomarker+Treatment); 3) the contrast of the interaction between treatment &amp; biomarker expression within ER Negative subjects from the full model(PCR~Biomarker:Treatment:ER). A:B represents A,B &amp; A*B.</description>
        <time_frame>pCR evaluated at time of surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy obtained prior to treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Randomized Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Randomized Participants With Non-missing pCR &amp; Biomarker Expression (GENE [Probe Set]), to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR</title>
          <description>Relevance of biomarker in differentiation between ixabepilone &amp; paclitaxel evaluated by logistic regression with pCR as response. Statistical analyses include: 1) the likelihood ratio test between the full model (PCR~Biomarker:Treatment:estrogen receptor [ER]) &amp; reduced model (PCR~Treatment:ER); 2) the likelihood ratio test between the full model (PCR~Biomarker:Treatment) &amp; reduced model (PCR~Biomarker+Treatment); 3) the contrast of the interaction between treatment &amp; biomarker expression within ER Negative subjects from the full model(PCR~Biomarker:Treatment:ER). A:B represents A,B &amp; A*B.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ABCB1 (209993_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCB1 /// ABCB4 (209994_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA1 (211851_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA1 (204531_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERCC1 (203719_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERCC1 (203720_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GTSE1 (204315_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GTSE1 (204317_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GTSE1 (215942_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GTSE1 (204318_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GTSE1 (211040_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KLK10 (209792_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KLK10 (215808_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KLK5 (222242_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KLK6 (204733_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RRM1 (201476_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RRM1 (201477_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB (211714_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB (212320_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB (209026_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB1 (208601_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB2A (204141_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB2A /// TUBB2B (209372_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB2B (214023_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB2C (208977_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB2C (213726_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB4 (212664_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB6 (209191_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TYMS (202589_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TYMS (217684_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ABCB1 (209993_at)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4115</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ABCB1 209993_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1629</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ABCB1 209993_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5074</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ABCB1 /// ABCB4 209994_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5530</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ABCB1 /// ABCB4 209994_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1845</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ABCB1 /// ABCB4 209994_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3538</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>BRCA1 211851_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9751</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>BRCA1 211851_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8874</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>BRCA1 211851_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6907</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>BRCA1 204531_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8052</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>BRCA1 204531_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5031</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>BRCA1 204531_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7588</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ERCC1 203719_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1542</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ERCC1 203719_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0235</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ERCC1 203719_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3612</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ERCC1 203720_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1840</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ERCC1 203720_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0942</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ERCC1 203720_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5327</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204315_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8847</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204315_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8947</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204315_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4085</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204317_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1119</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204317_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0250</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204317_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3569</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 215942_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4103</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 215942_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1490</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 215942_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5590</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204318_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4796</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204318_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2794</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204318_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1646</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 211040_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0782</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 211040_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1407</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 211040_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2369</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK10 209792_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7756</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK10 209792_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2623</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK10 209792_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3147</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK10 215808_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2885</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK10 215808_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7187</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK10 215808_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6017</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK5 222242_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4500</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK5 222242_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0952</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK5 222242_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7069</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK6 204733_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4767</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK6 204733_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6191</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK6 204733_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5276</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>RRM1 201476_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3323</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>RRM1 201476_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1025</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>RRM1 201476_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1715</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>RRM1 201477_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1070</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>RRM1 201477_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2751</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>RRM1 201477_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0276</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 211714_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1689</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 211714_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0769</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 211714_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1058</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 212320_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6406</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 212320_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1733</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 212320_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2631</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 209026_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2170</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 209026_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0868</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 209026_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1117</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB1 (208601_s_at)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4943</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB1 208601_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5190</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB1 208601_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7350</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2A 204141_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3820</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2A 204141_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9290</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2A 204141_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0699</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2A /// TUBB2B 209372_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3515</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2A /// TUBB2B 209372_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2128</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2A /// TUBB2B 209372_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1275</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2B 214023_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2158</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2B 214023_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0266</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2B 214023_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3636</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2C 208977_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9479</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2C 208977_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3753</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2C 208977_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5477</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2C 213726_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4760</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2C 213726_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3314</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2C 213726_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1005</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB4 212664_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1180</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB4 212664_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1580</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB4 212664_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4385</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB6 209191_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7324</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB6 209191_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2657</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB6 209191_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5637</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TYMS 202589_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4473</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TYMS 202589_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3292</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TYMS 202589_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2054</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TYMS 217684_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5226</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment: ER) and the reduced model: (PCR ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TYMS 217684_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1720</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR ~ Biomarker: Treatment) and the reduced model: (PCR ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TYMS 217684_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3346</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Randomized Participants With Non-missing pCR &amp; Biomarker Expression (GENE [Probe Set]) to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR/RCB1</title>
        <description>Relevance of biomarker in differentiation between ixabepilone &amp; paclitaxel evaluated by logistic regression with pCR/RCB1 as response. Statistical analyses include: 1) likelihood ratio test between the full model (pCR/RCB1~Biomarker:Treatment: ER) &amp; reduced model (pCR/RCB1~Treatment:ER); 2) likelihood ratio test between the full model (pCR/RCB1 Biomarker:Treatment) &amp; reduced model (pCR/RCB1~Biomarker+Treatment); 3) contrast of the interaction between treatment &amp; biomarker expression within ER Negative subjects from the full model (pCR/RCB1~Biomarker:Treatment:ER). A:B represents A,B &amp; A*B.</description>
        <time_frame>pCR evaluated at time of surgery (4-6 weeks after the last dose of therapy); mandatory tumor tissue biopsy obtained prior to treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Randomized Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Randomized Participants With Non-missing pCR &amp; Biomarker Expression (GENE [Probe Set]) to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR/RCB1</title>
          <description>Relevance of biomarker in differentiation between ixabepilone &amp; paclitaxel evaluated by logistic regression with pCR/RCB1 as response. Statistical analyses include: 1) likelihood ratio test between the full model (pCR/RCB1~Biomarker:Treatment: ER) &amp; reduced model (pCR/RCB1~Treatment:ER); 2) likelihood ratio test between the full model (pCR/RCB1 Biomarker:Treatment) &amp; reduced model (pCR/RCB1~Biomarker+Treatment); 3) contrast of the interaction between treatment &amp; biomarker expression within ER Negative subjects from the full model (pCR/RCB1~Biomarker:Treatment:ER). A:B represents A,B &amp; A*B.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ABCB1 (209993_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABCB1 /// ABCB4 (209994_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA1 (211851_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA1 (204531_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERCC1 (203719_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERCC1 (203720_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GTSE1 (204315_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GTSE1 (204317_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GTSE1 (215942_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GTSE1 (204318_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GTSE1 (211040_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KLK10 (209792_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KLK10 (215808_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KLK5 (222242_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KLK6 (204733_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RRM1 (201476_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RRM1 (201477_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB (211714_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB (212320_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB (209026_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB1 (208601_s_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB2A (204141_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB2A /// TUBB2B (209372_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB2B (214023_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB2C (208977_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB2C (213726_x_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB4 (212664_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TUBB6 (209191_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TYMS (202589_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TYMS (217684_at)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ABCB1 209993_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5604</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ABCB1 209993_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2715</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ABCB1 209993_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5268</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ABCB1 /// ABCB4 209994_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6058</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ABCB1 /// ABCB4 209994_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1918</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ABCB1 /// ABCB4 209994_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6712</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>BRCA1 211851_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9195</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>BRCA1 211851_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7021</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>BRCA1 211851_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3910</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>BRCA1 204531_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2909</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>BRCA1 204531_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3336</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>BRCA1 204531_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2360</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ERCC1 203719_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0281</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ERCC1 203719_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0434</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ERCC1 203719_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0283</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ERCC1 203720_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0151</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ERCC1 203720_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1999</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>ERCC1 203720_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0146</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204315_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1185</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204315_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8705</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204315_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0284</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204317_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0399</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204317_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0136</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204317_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0576</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 215942_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2245</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 215942_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1388</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 215942_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0692</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204318_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1058</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204318_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2688</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 204318_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0192</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 211040_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0033</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 211040_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2053</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>GTSE1 211040_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK10 209792_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6783</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK10 209792_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1630</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK10 209792_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2944</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK10 215808_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3727</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK10 215808_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8796</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK10 215808_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8344</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK5 222242_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2700</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK5 222242_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2624</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK5 222242_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0830</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK6 204733_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0849</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK6 204733_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6578</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>KLK6 204733_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0396</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>RRM1 201476_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1657</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>RRM1 201476_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0675</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>RRM1 201476_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1071</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>RRM1 201477_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0142</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>RRM1 201477_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2465</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>RRM1 201477_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0031</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 211714_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1231</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 211714_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0849</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 211714_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2740</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 212320_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2383</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 212320_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0644</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 212320_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2866</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 209026_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1259</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 209026_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0718</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB 209026_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3170</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB1 208601_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7844</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB1 208601_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4688</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB1 208601_s_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8553</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2A 204141_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6926</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2A 204141_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2222</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2A 204141_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4676</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2A /// TUBB2B 209372_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2036</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2A /// TUBB2B 209372_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4197</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2A /// TUBB2B 209372_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0776</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2B 214023_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4076</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2B 214023_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0629</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2B 214023_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2547</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2C 208977_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7125</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2C 208977_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6001</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2C 208977_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5398</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2C 213726_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3970</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2C 213726_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5085</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB2C 213726_x_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1213</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB4 212664_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0999</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB4 212664_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1201</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB4 212664_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1172</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB6 209191_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6596</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB6 209191_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3289</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TUBB6 209191_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3657</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TYMS 202589_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0275</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TYMS 202589_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3946</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TYMS 202589_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0074</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TYMS 217684_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2341</p_value>
            <p_value_desc>P Value 1 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment: ER) and the reduced model: (PCR/RCB1 ~ Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TYMS 217684_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0933</p_value>
            <p_value_desc>P Value 2 is from the likelihood ratio test between the full model: (PCR/RCB1 ~ Biomarker: Treatment) and the reduced model: (PCR/RCB1 ~ Biomarker + Treatment)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TYMS 217684_at</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2016</p_value>
            <p_value_desc>P Value 3 is the contrast of the interaction between treatment and biomarker expression within ER Negative subjects from the full model:(PCR/RCB1 ~ Biomarker : Treatment : ER)</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>p-value not adjusted for multiple comparison</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With pCR and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-Specified Thresholds</title>
        <description>Percentage of participants with pCR in MDR1 IHC positive and negative groups using 2 pre-specified thresholds,. The first pre-specified threshold for MDR1-positivity (Mem) =Any membrane staining. The second pre-specified threshold for MDR1-positivity (Mem+Cyto)=Any membrane staining or at least 200 Cytoplasmic H-score.</description>
        <time_frame>: pCR evaluated at time of surgery (4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy obtained prior to treatment.</time_frame>
        <population>Randomized participants with non-missing pCR and biomarker expression</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With pCR and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-Specified Thresholds</title>
          <description>Percentage of participants with pCR in MDR1 IHC positive and negative groups using 2 pre-specified thresholds,. The first pre-specified threshold for MDR1-positivity (Mem) =Any membrane staining. The second pre-specified threshold for MDR1-positivity (Mem+Cyto)=Any membrane staining or at least 200 Cytoplasmic H-score.</description>
          <population>Randomized participants with non-missing pCR and biomarker expression</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mem+Cyto Threshold/Negative Biomarker Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.143" lower_limit="0.069" upper_limit="0.252"/>
                    <measurement group_id="O2" value="0.288" lower_limit="0.193" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mem+Cyto Threshold/Positive Biomarker Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.323" lower_limit="0.225" upper_limit="0.433"/>
                    <measurement group_id="O2" value="0.259" lower_limit="0.167" upper_limit="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mem Threshold/Negative Biomarker Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.228" lower_limit="0.158" upper_limit="0.312"/>
                    <measurement group_id="O2" value="0.284" lower_limit="0.211" upper_limit="0.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mem Threshold/Negative Biomarker Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.316" lower_limit="0.147" upper_limit="0.53"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.057" upper_limit="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mem+Cyto Threshold/Negative Biomarker Status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (bootstrap method)</param_type>
            <param_value>-0.145</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>-0.017</ci_upper_limit>
            <estimate_desc>ixabepilone - paclitaxel</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mem+Cyto Threshold/Positive Biomarker STatus</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (bootstrap method)</param_type>
            <param_value>0.064</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.064</ci_lower_limit>
            <ci_upper_limit>0.197</ci_upper_limit>
            <estimate_desc>ixabepilone - paclitaxel</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Membrane Threshold/Negative Biomarker Status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (bootstrap method)</param_type>
            <param_value>-0.056</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.152</ci_lower_limit>
            <ci_upper_limit>0.046</ci_upper_limit>
            <estimate_desc>ixabepilone - paclitaxel</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Membrane Threshold/Positive Biomarker Status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (bootstrap method)</param_type>
            <param_value>0.116</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
            <estimate_desc>ixabepilone - paclitaxel</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With pCR/RCB1 and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-specified Thresholds</title>
        <description>Percentage of participants with pCR/RCB1 in MDR1 IHC positive and negative groups using 2 pre-specified thresholds,. The first pre-specified threshold for MDR1-positivity (Mem) =Any membrane staining. The second pre-specified threshold for MDR1-positivity (Mem+Cyto)=Any membrane staining or at least 200 Cytoplasmic H-score .</description>
        <time_frame>pCR evaluated at time of surgery (4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy obtained prior to treatment.</time_frame>
        <population>Randomized participants with non-missing pCR/RCB1 and biomarker expression</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With pCR/RCB1 and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-specified Thresholds</title>
          <description>Percentage of participants with pCR/RCB1 in MDR1 IHC positive and negative groups using 2 pre-specified thresholds,. The first pre-specified threshold for MDR1-positivity (Mem) =Any membrane staining. The second pre-specified threshold for MDR1-positivity (Mem+Cyto)=Any membrane staining or at least 200 Cytoplasmic H-score .</description>
          <population>Randomized participants with non-missing pCR/RCB1 and biomarker expression</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mem+Cyto Threshold/Negative Biomarker Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.224" lower_limit="0.131" upper_limit="0.344"/>
                    <measurement group_id="O2" value="0.339" lower_limit="0.237" upper_limit="0.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mem+Cyto Threshold/Positive Biomarker Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.371" lower_limit="0.268" upper_limit="0.483"/>
                    <measurement group_id="O2" value="0.362" lower_limit="0.257" upper_limit="0.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mem Threshold/Negative Biomarker Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.304" lower_limit="0.226" upper_limit="0.393"/>
                    <measurement group_id="O2" value="0.363" lower_limit="0.283" upper_limit="0.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mem Threshold/Negative Biomarker Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.316" lower_limit="0.147" upper_limit="0.53"/>
                    <measurement group_id="O2" value="0.267" lower_limit="0.097" upper_limit="0.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mem+Cyto/Negative Biomarker Status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (bootstrap method)</param_type>
            <param_value>-0.114</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.258</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
            <estimate_desc>ixabepilone - paclitaxel</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mem+Cyto Threshold/Positive Biomarker Status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>DIfference (bootstrap method)</param_type>
            <param_value>0.009</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.137</ci_lower_limit>
            <ci_upper_limit>0.155</ci_upper_limit>
            <estimate_desc>ixabepilone - paclitaxel</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Membrane Threshold/Negative Biomarker Status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (bootstrap method)</param_type>
            <param_value>-0.058</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.167</ci_lower_limit>
            <ci_upper_limit>0.053</ci_upper_limit>
            <estimate_desc>ixabepilone - paclitaxel</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Membrane Threshold/Positive Biomarker Status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (bootstrap method)</param_type>
            <param_value>0.049</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.227</ci_lower_limit>
            <ci_upper_limit>0.309</ci_upper_limit>
            <estimate_desc>ixabepilone - paclitaxel</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With pCR and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-specified Thresholds, Estrogen-Receptor (ER) Negative Participants</title>
        <description>Percentage of ER negative participants with pCR and MDR1 immunohistochemistry (IHC) positivity using 2 pre-specified thresholds, stratified by biomarker status. The first pre-specified threshold for MDR1-positivity (Mem)=Any membrane staining. The second pre-specified threshold for MDR1-positivity (Mem+Cyto)=Any membrane staining or at least 200 Cytoplasmic H-score.</description>
        <time_frame>pCR evaluated at time of surgery (4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy obtained prior to treatment.</time_frame>
        <population>Randomized estrogen negative participants with non-missing pCR and biomarker expression</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With pCR and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-specified Thresholds, Estrogen-Receptor (ER) Negative Participants</title>
          <description>Percentage of ER negative participants with pCR and MDR1 immunohistochemistry (IHC) positivity using 2 pre-specified thresholds, stratified by biomarker status. The first pre-specified threshold for MDR1-positivity (Mem)=Any membrane staining. The second pre-specified threshold for MDR1-positivity (Mem+Cyto)=Any membrane staining or at least 200 Cytoplasmic H-score.</description>
          <population>Randomized estrogen negative participants with non-missing pCR and biomarker expression</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mem+Cyto Threshold/Negative Biomarker Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.192" lower_limit="0.079" upper_limit="0.363"/>
                    <measurement group_id="O2" value="0.483" lower_limit="0.32" upper_limit="0.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mem+Cyto Threshold/Positive Biomarker Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.447" lower_limit="0.309" upper_limit="0.593"/>
                    <measurement group_id="O2" value="0.341" lower_limit="0.22" upper_limit="0.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mem Threshold/Negative Biomarker Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.327" lower_limit="0.22" upper_limit="0.449"/>
                    <measurement group_id="O2" value="0.417" lower_limit="0.309" upper_limit="0.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mem Threshold/Negative Biomarker Status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.417" lower_limit="0.181" upper_limit="0.685"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.087" upper_limit="0.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mem+Cyto Threshold/Negative Biomarker Status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (bootstrap method)</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.482</ci_lower_limit>
            <ci_upper_limit>-0.094</ci_upper_limit>
            <estimate_desc>ixabepilone - paclitaxel</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mem+Cyto Threshold/Positive Biomarker Status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (boostrap method)</param_type>
            <param_value>0.106</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.073</ci_lower_limit>
            <ci_upper_limit>0.291</ci_upper_limit>
            <estimate_desc>ixabepilone - paclitaxel</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Membrane Threshold/Negative Biomarker Status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (bootstrap method)</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.236</ci_lower_limit>
            <ci_upper_limit>0.067</ci_upper_limit>
            <estimate_desc>ixabepilone - paclitaxel</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mem+Cyto Threshold/Positive Biomarker Status</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (bootsrap method)</param_type>
            <param_value>0.117</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.218</ci_lower_limit>
            <ci_upper_limit>0.469</ci_upper_limit>
            <estimate_desc>ixabepilone - paclitaxel</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Biomarker Based on Optimal Threshold (Biomarker Positive Participants)</title>
        <description>Percentage of participants having the following optimal biomarker thresholds as computed from the cross-validation method (cutoff of biomarker positive [with 90% confidence interval by Bootstrap method]): Beta 3 Tubulin IHC (45.866 [5, 83.9]); TACC3 mRNA (6.714 [6.312, 7.192]); CAPG mRNA (6.739 [5.728, 7.298]). Optimal thresholds for a 20-gene model and a 26-gene model were also planned; however, these were not determined because preliminary analyses did not indicate that they would not differentiate pCR rates between treatment arm.</description>
        <time_frame>pCR evaluated at time of surgery (4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy and mRNA samples obtained prior to treatment</time_frame>
        <population>Randomized participants with non-missing pCR and biomarker expressions. n=the number of participants with specific biomarker expression.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Participants</title>
            <description>Randomized Participants with non-missing pCR and biomarker expression</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Biomarker Based on Optimal Threshold (Biomarker Positive Participants)</title>
          <description>Percentage of participants having the following optimal biomarker thresholds as computed from the cross-validation method (cutoff of biomarker positive [with 90% confidence interval by Bootstrap method]): Beta 3 Tubulin IHC (45.866 [5, 83.9]); TACC3 mRNA (6.714 [6.312, 7.192]); CAPG mRNA (6.739 [5.728, 7.298]). Optimal thresholds for a 20-gene model and a 26-gene model were also planned; however, these were not determined because preliminary analyses did not indicate that they would not differentiate pCR rates between treatment arm.</description>
          <population>Randomized participants with non-missing pCR and biomarker expressions. n=the number of participants with specific biomarker expression.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Beta 3 Tubulin IHC (n=231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.394" lower_limit="0.242" upper_limit="0.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta 3 Tubulin IHC H-Score (n=231)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.299" lower_limit="0.173" upper_limit="0.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta 3 Tubulin mRNA (n=245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.392" lower_limit="0.167" upper_limit="0.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TACC3 mRNA (n=245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.514" lower_limit="0.273" upper_limit="0.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CAPG mRNA (n=245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.486" lower_limit="0.294" upper_limit="0.767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Safety Summary: Deaths, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Drug-Related AEs, and Most Common Treatment-Related Non-Hematologic Adverse Events (TNAEs) Occuring in &gt;=10% of Participants</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. By Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grades</description>
        <time_frame>prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of 12 weeks of study therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Safety Summary: Deaths, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Drug-Related AEs, and Most Common Treatment-Related Non-Hematologic Adverse Events (TNAEs) Occuring in &gt;=10% of Participants</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. By Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grades</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE, Grade (Gr) 1 (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE, Grade 2 (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE, Grade 3 (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE, Grade 4 (life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE, Grade 5 (death)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE, Grade Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Leading to Discontinuation, Grade 1 (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Leading to Discontinuation, Grade 2 (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Leading to Discontinuation, Grade 3 (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Leading to Discon, Grade 4 (life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drug-Related AE, Grade 1 (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drug-Related AE, Grade 2 (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drug-Related AE, Grade 3 (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drug-Related AE, Grade 4 (life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Peripheral Sensory Neuropathy,Grade 1 (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE:Peripheral Sensory Neuropathy,Gr 2 (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Peripheral Sensory Neuropathy, Gr 3 (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Peripheral Sensory Neuropathy, Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Myalgia, Grade 1 (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Myalgia, Grade 2 (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Myalgia, Grade 3 (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Myalgia, Grade 4 (life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Arthralgia, Grade 1 (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Arthralgia, Grade 2 (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Arthralgia, Grade 3 (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Arthralgia, Grade 4 (life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Bone Pain, Grade 1 (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Bone Pain, Grade 2 (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Bone Pain, Grade 3 (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Bone Pain, Grade 4 (life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Fatigue, Grade 1 (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Fatigue, Grade 2 (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Fatigue, Grade 3 (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Fatigue, Grade 4 (life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Diarrhea, Grade 1 (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Diarrhea, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Diarrhea, Grade 3 (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Diarrhea, Grade 4 (life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Nausea, Grade 1 (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Nausea, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Nausea, Grade 3 (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Nausea, Grade 4 (life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Musculoskeletal Pain, Grade 1 (mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Musculoskeletal Pain, Grade 2 (moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Musculoskeletal Pain, Grade 3 (severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNAE: Musculoskeletal Pain,Gr 4 (life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Any Drug-Related AEs and Gastrointestinal AEs by System Organ Class</title>
        <description>MCT=musculoskeletal and connective tissue, GDASC=general disorders and administration site conditions, RTM=respiratory, thoracic and mediastinal disorders, NBMUCP=neoplasms benign, malignant and unspecified (including cysts and polyps). Drug related adverse events are those events with relationship to study therapy of certain, probable, possible or missing. Subjects may have more than one event within a class. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)</description>
        <time_frame>prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of 12 weeks of study therapy</time_frame>
        <population>Ixabepilone- and Paclitaxel-treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Any Drug-Related AEs and Gastrointestinal AEs by System Organ Class</title>
          <description>MCT=musculoskeletal and connective tissue, GDASC=general disorders and administration site conditions, RTM=respiratory, thoracic and mediastinal disorders, NBMUCP=neoplasms benign, malignant and unspecified (including cysts and polyps). Drug related adverse events are those events with relationship to study therapy of certain, probable, possible or missing. Subjects may have more than one event within a class. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)</description>
          <population>Ixabepilone- and Paclitaxel-treated participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Drug-Related AEs, Grade (Gr) 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drug-Related AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drug-Related AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drug-Related AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drug-Related AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Disorder AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCT Disorder AEs, Gr 1 (spell out)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCT Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCT Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCT Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCT Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GDASC AEs, Gr 1 (spell out)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GDASC AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GDASC AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GDASC AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GDASC AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and Subcutaneous Tissue Disorder AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and Subcutaneous Tissue Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and Subcutaneous Tissue Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and Subcutaneous Tissue Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and Subcutaneous Tissue Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous System Disorder AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous System Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous System Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous System Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous System Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood &amp; Lymphatic System Disorder AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood &amp; Lymphatic System Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood &amp; Lymphatic System Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood &amp; Lymphatic System Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood &amp; Lymphatic System Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laboratory Investigation AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laboratory Investigation AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laboratory Investigation AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laboratory Investigation AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laboratory Investigation AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism &amp; Nutrition Disorder AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism &amp; Nutrition Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism &amp; Nutrition Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism &amp; Nutrition Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism &amp; Nutrition Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RTM Disorder AEs, Gr 1 (spell out)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RTM Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RTM Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RTM Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RTM Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections &amp; Infestations AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections &amp; Infestations AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections &amp; Infestations AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections &amp; Infestations AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections &amp; Infestations, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric Disorder AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Disorder AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye Disorder AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immune System Disorder AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immune System Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immune System Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immune System Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immune System Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reproductive System and Breast Disorders, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reproductive System and Breast Disorders, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reproductive System and Breast Disorders, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reproductive System and Breast Disorders, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reproductive System and Breast Disorders, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Disorder AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear and Labyrinth Disorder AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear and Labyrinth Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear and Labyrinth Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear and Labyrinth Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear and Labyrinth Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and Urinary Disorder AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and Urinary Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and Urinary Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and Urinary Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and Urinary Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, Poisoning&amp;Procedural Complication AEs,Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, Poisoning&amp;Procedural Complication AEs,Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, Poisoning&amp;Procedural Complication AEs,Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, Poisoning&amp;Procedural Complication AEs,Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, Poisoning&amp;Procedural Complication AEs,Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary Disorder AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary Disorder AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary Disorder AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary Disorder AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatobiliary Disorder AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NBMUCP AEs, Gr 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NBMUCP AEs, Gr 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NBMUCP AEs, Gr 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NBMUCP AEs, Gr 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NBMUCP AEs, Gr 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>On-Study Hematology: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)</description>
        <time_frame>prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of 12 weeks of study therapy during ixabepilone or paclitaxel treatment phase</time_frame>
        <population>Ixabepilone/Paclitaxel treated participants for whom on-study labs were recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>On-Study Hematology: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)</description>
          <population>Ixabepilone/Paclitaxel treated participants for whom on-study labs were recorded.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>White Blood Cells (WBC), Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Grade 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophil Count (ANC), Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANC, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANC, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANC, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANC, Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANC, Grade 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANC, Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Grade 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Grade 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Pathologic Complete Response (pCR) in Biomarker-Defined Populations</title>
        <description>Beta III tubulin positivity determined by cross-validation method. Optimal cutoff: ≥46% tumor cells staining at 2 plus or 3 plus intensity (corresponding Beta III tubulin positivity=39.4%). Pre-specified cutoff of Beta III tubulin positivity: ≥50% 2plus or 3plus cells (corresponding prevalence=38.5%). Optimal cutoffs for TACC3 and CAPG positivity determined by cross-validation method: 6.889 and 6.844 [log2 normalized intensity units], respectively (corresponding to prevalence rates of 43.3% and 44.3%).</description>
        <time_frame>pCR evaluated at time of surgery (4-6 weeks after the last dose of therapy); mandatory tumor tissue biopsy obtained prior to treatment.</time_frame>
        <population>For all subgroups other than Beta-III positive/negative subgroup based on a pre-determined cutoff, results were estimated using a cross-validation method (a resampling based technique, making individual sample size [N] not applicable).</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Pathologic Complete Response (pCR) in Biomarker-Defined Populations</title>
          <description>Beta III tubulin positivity determined by cross-validation method. Optimal cutoff: ≥46% tumor cells staining at 2 plus or 3 plus intensity (corresponding Beta III tubulin positivity=39.4%). Pre-specified cutoff of Beta III tubulin positivity: ≥50% 2plus or 3plus cells (corresponding prevalence=38.5%). Optimal cutoffs for TACC3 and CAPG positivity determined by cross-validation method: 6.889 and 6.844 [log2 normalized intensity units], respectively (corresponding to prevalence rates of 43.3% and 44.3%).</description>
          <population>For all subgroups other than Beta-III positive/negative subgroup based on a pre-determined cutoff, results were estimated using a cross-validation method (a resampling based technique, making individual sample size [N] not applicable).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Beta-III positive subgroup (cross-validation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" lower_limit="20.6" upper_limit="53.2"/>
                    <measurement group_id="O2" value="36.1" lower_limit="23.3" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta-III negative subgroup (cross-validation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="10.3" upper_limit="27.1"/>
                    <measurement group_id="O2" value="22.4" lower_limit="13.1" upper_limit="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta-III positive subgroup (n=43, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" lower_limit="22.9" upper_limit="48.5"/>
                    <measurement group_id="O2" value="35.7" lower_limit="23.5" upper_limit="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta-III negative subgroup (n=71, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="11.2" upper_limit="27.5"/>
                    <measurement group_id="O2" value="22.7" lower_limit="15.0" upper_limit="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TACC3 positive subgroup (cross-validation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" lower_limit="18.1" upper_limit="37.9"/>
                    <measurement group_id="O2" value="29.4" lower_limit="19.6" upper_limit="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TACC3 negative subgroup (cross-validation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" lower_limit="10.8" upper_limit="30.7"/>
                    <measurement group_id="O2" value="27.0" lower_limit="13.2" upper_limit="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CAPG positive subgroup (cross-validation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" lower_limit="18.9" upper_limit="47.4"/>
                    <measurement group_id="O2" value="35.3" lower_limit="24.0" upper_limit="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CAPG negative subgroup (cross-validation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4" lower_limit="11.4" upper_limit="31.5"/>
                    <measurement group_id="O2" value="20.7" lower_limit="9.1" upper_limit="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>On-Study Liver Function: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase</title>
        <description>Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST). AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)</description>
        <time_frame>prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of study therapy during ixabepilone or paclitaxel treatment phase</time_frame>
        <population>Ixabepilone/Paclitaxel treated participants for whom on-study labs were recorded; n=number of participants with specific laboratory evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>On-Study Liver Function: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase</title>
          <description>Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST). AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)</description>
          <population>Ixabepilone/Paclitaxel treated participants for whom on-study labs were recorded; n=number of participants with specific laboratory evaluation.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, Grade 0 (n=142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Grade 1 (n=142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Grade 2 (n=142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Grade 3 (n=142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Grade 4 (n=142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Grade 1-4 (n=142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Grade 3-4 (n=142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Grade 0 (n=141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Grade 1 (n=141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Grade 2 (n=141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Grade 3 (n=141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Grade 4 (n=141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Grade 1-4 (n=141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Grade 3-4 (n=141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase, Grade 0 (n=141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase, Grade 1 (n=141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase, Grade 2 (n=141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase, Grade 3 (n=141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase, Grade 4 (n=141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase, Grade 1-4 (n=141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase, Grade 3-4 (n=141, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, Grade 0 (n=142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, Grade 1 (n=142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, Grade 2 (n=142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, Grade 3 (n=142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, Grade 4 (n=142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, Grade 1-4 (n=142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, Grade 3-4 (n=142, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>On-Study Renal Function: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)</description>
        <time_frame>prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of 12 weeks of study therapy during ixabepilone or paclitaxel treatment phase</time_frame>
        <population>Ixabepilone/Paclitaxel treated participants for whom on-study labs were recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>On-Study Renal Function: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)</description>
          <population>Ixabepilone/Paclitaxel treated participants for whom on-study labs were recorded.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine, Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Grade 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Grade 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants by Dose for AC</title>
        <time_frame>12 weeks (4 3-week cycles)</time_frame>
        <population>ixabepilone- and paclitaxel-treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants by Dose for AC</title>
          <population>ixabepilone- and paclitaxel-treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1 (Week 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 3 (Week 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 4 (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants by Dose for Ixabepilone/Paclitaxel</title>
        <time_frame>12 weeks (4 3-week cycles for ixabepilone and 12 weekly doses for paclitaxel)</time_frame>
        <population>ixabepilone- and paclitaxel-treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants by Dose for Ixabepilone/Paclitaxel</title>
          <population>ixabepilone- and paclitaxel-treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1 (Week 3, ixabepilone; Week 1 paclitaxel)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 (Week 6, ixabepilone; Week 2 paclitaxel)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 3 (Week 9, ixabepilone; Week 3 paclitaxel)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 4 (Week 12, ixabepilone; Week 4 paclitaxel)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 5 (Week 5 paclitaxel)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 6 (Week 6 paclitaxel)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 7 (Week 7 paclitaxel)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 8 (Week 8 paclitaxel)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 9 (Week 9 paclitaxel)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 10 (Week 10 paclitaxel)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 11 (Week 11 paclitaxel)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 12 (Week 12 paclitaxel)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reason for First Dose Reduction of AC</title>
        <time_frame>12 weeks (4 3-week cycles)</time_frame>
        <population>ixabepilone- and paclitaxel-treated participants with at least 2 courses of AC</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Reason for First Dose Reduction of AC</title>
          <population>ixabepilone- and paclitaxel-treated participants with at least 2 courses of AC</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with at least 1 dose reduction of AC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematologic Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hematologic Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reason for First Dose Reduction of Ixabepilone/Paclitaxel</title>
        <time_frame>12 weeks (4 3-week cycles for ixabepilone and 12 weekly doses for paclitaxel)</time_frame>
        <population>ixabepilone- and paclitaxel-treated participants with at least 2 courses of Ixabepilone/Paclitaxel</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Reason for First Dose Reduction of Ixabepilone/Paclitaxel</title>
          <population>ixabepilone- and paclitaxel-treated participants with at least 2 courses of Ixabepilone/Paclitaxel</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with at least 1 dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematologic Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hematologic Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral Neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Course Delay and Reason for Delay for AC</title>
        <time_frame>12 weeks (4 3-week cycles)</time_frame>
        <population>ixabepilone- and paclitaxel-treated participants with at least 2 courses of AC</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Course Delay and Reason for Delay for AC</title>
          <population>ixabepilone- and paclitaxel-treated participants with at least 2 courses of AC</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with at least 1 dose delay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Administrative Reason</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematologic Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hematologic Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject Request</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Dose Delay and Reason for Dose Delay for Ixabepilone/Paclitaxel</title>
        <time_frame>12 weeks (4 3-week cycles for ixabepilone and 12 weekly doses for paclitaxel)</time_frame>
        <population>ixabepilone- and paclitaxel-treated participants with at least 2 courses of Ixabepilone/Paclitaxel</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Delay and Reason for Dose Delay for Ixabepilone/Paclitaxel</title>
          <population>ixabepilone- and paclitaxel-treated participants with at least 2 courses of Ixabepilone/Paclitaxel</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with at least 1 dose delay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Administrative Reason</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematologic Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hematologic Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral Neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject Request</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Pathologic Complete Response (pCR) in 20- and 26-Gene Model Subgroups</title>
        <description>For each of the 2 biomarker sets (20-gene or 26-gene), a multi-gene model was built using penalized logistic regression on all pharmacogenomic evaluable subjects for each treatment arm separately. Receiver Operating Characteristic (ROC) plots for separate arm using 5 fold cross validation were generated. ROC for separate arms using cross over were also added. Further analysis on the multiple gene models (as mentioned in the SAP) was planned only based on the initial findings from the 2 ROC plots. For 20- and 26-gene models, ROC curves generated for each study arm did not indicate that these multi-gene models differentially predicted for pCR between the treatment arms, so further analyses to estimate the optimal cut-off and the pCR rates were not conducted.</description>
        <time_frame>pCR evaluated at time of surgery (4-6 weeks after the last dose of therapy); mandatory tumor tissue biopsy obtained prior to treatment.</time_frame>
        <population>For 20- and 26-gene models, ROC curves generated for each study arm did not indicate that these multi-gene models differentially predicted for pCR between the treatment arms, so further analyses to estimate the optimal cut-off and the pCR rates were not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone</title>
            <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel</title>
            <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Pathologic Complete Response (pCR) in 20- and 26-Gene Model Subgroups</title>
          <description>For each of the 2 biomarker sets (20-gene or 26-gene), a multi-gene model was built using penalized logistic regression on all pharmacogenomic evaluable subjects for each treatment arm separately. Receiver Operating Characteristic (ROC) plots for separate arm using 5 fold cross validation were generated. ROC for separate arms using cross over were also added. Further analysis on the multiple gene models (as mentioned in the SAP) was planned only based on the initial findings from the 2 ROC plots. For 20- and 26-gene models, ROC curves generated for each study arm did not indicate that these multi-gene models differentially predicted for pCR between the treatment arms, so further analyses to estimate the optimal cut-off and the pCR rates were not conducted.</description>
          <population>For 20- and 26-gene models, ROC curves generated for each study arm did not indicate that these multi-gene models differentially predicted for pCR between the treatment arms, so further analyses to estimate the optimal cut-off and the pCR rates were not conducted.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events are reported for randomized population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ixabepilone</title>
          <description>ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)</description>
        </group>
        <group group_id="E2">
          <title>Paclitaxel</title>
          <description>paclitaxel 80 mg/m^2 administered IV every week for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>THROMBOTIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>GALLSTONE ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>MEDICATION ERROR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>CRANIAL NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>CEREBRAL VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>NON-CARDIOGENIC PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>EXFOLIATIVE RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>NAIL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

